Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela?s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in horses. The license agreement is subject to, among other things, EQGen Biomedical securing financing from its extensive, qualified investor network.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.274 SEK | +1.48% |
|
+6.20% | +1.11% |
24/05 | Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
23/05 | Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses | CI |
1st Jan change | Capi. | |
---|---|---|
+1.11% | 14.53M | |
+38.95% | 53.67B | |
+33.67% | 38.86B | |
-8.26% | 38.76B | |
-10.77% | 27.27B | |
+11.68% | 25.91B | |
-15.81% | 20.29B | |
+33.99% | 12.78B | |
+28.11% | 12.18B | |
-2.90% | 11.96B |
- Stock Market
- Equities
- XINT Stock
- News Xintela AB
- Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses